GCM
KRTX

Graham Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Graham Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,515
Closed -$572K – 1301
2022
Q1 		$572K Buy
+4,515
New +$508K 0.02% 509

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Graham Capital Management's KRTX Position: Q2 2022 in Review

Graham Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2022, closing a stake of 4,515 shares — an estimated $572K sold.

Graham Capital Management first reported a position in KRTX in Q1 2022 and held it in 1 quarter. The position peaked at $572K in Q1 2022. 195 funds tracked by Wall St. Rank hold KRTX as of Q2 2022.

  • Graham Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Graham Capital Management sold 4,515 Karuna Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $572K.
  • Graham Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Graham Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $572K in Q1 2022.
  • 195 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Graham Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.